Urine analysis of cfDNA BRAF V600E mutations in urine provides a reliable method of detecting mutation status and may be useful as a biomarker to monitor response to treatment in Langerhans Cell Histiocytosis and Erdheim-Chester Disease. Here, BRAF is linked to Erdheim-Chester disease.